Major coronary heart disease event excluding revascularizations

I9_CHD_NOREV

intermediate coronary syndrome: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 I20.0, I21, I22
Hospital discharge: ICD-9 410|4110
Hospital discharge: ICD-8 410|4110
Cause of death: ICD-10 I21, I22, I23, I24, I25, I46, R96, R98
Cause of death: ICD-9 41[0-4]|798
Cause of death: ICD-8 41[0-4]|798
Cause of death: excluded ICD-9 7980A

29825

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Check only main diagnosis Yes, side diagnoses are not checked
Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

28309

diagram downward connector

Check minimum number of events None

28309

diagram downward connector
diagram bullet diagram downward connector

Include endpoints

28373

diagram downward connector
I9_CHD_NOREV

Extra metadata

Level in the ICD hierarchy C
First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
Number of individuals 27443 8124 19319
Unadjusted prevalence (%) 8.89 4.68 14.31
Mean age at first event (years) 66.12 68.63 65.07

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.07 4.91 [4.44, 5.43] <1e-100 10293
15 years 0.01 2.25 [2.03, 2.49] 2.3e-53 3159
5 years 0.00 3.89 [3.55, 4.26] <1e-100 1905
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: I9_CHD_NOREV – Major coronary heart disease event excluding revascularizations
GWS hits: 22

Survival analyses between endpoints

Plot

before Major coronary heart disease event excluding revascularizations
after Major coronary heart disease event excluding revascularizations

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Major coronary heart disease event excluding revascularizations